Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective upped by Nomura to $86.00 in a report published on Friday, February 9th. They currently have a sell rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also commented on the company. BMO Capital Markets reduced their price target on Alnylam Pharmaceuticals from $165.00 to $160.00 and set an outperform rating on the stock in a research report on Friday, February 9th. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $128.00 to $118.00 and set an equal weight rating on the stock in a research note on Friday, February 9th. B. Riley began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They issued a buy rating and a $240.00 price objective for the company. Piper Jaffray Companies reissued a buy rating and issued a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. Finally, Needham & Company LLC reaffirmed a buy rating and set a $152.00 price target (up from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of Buy and a consensus target price of $126.76.
Alnylam Pharmaceuticals (ALNY) opened at $122.88 on Friday. The firm has a market capitalization of $12,271.76, a price-to-earnings ratio of -22.71 and a beta of 2.69. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals has a fifty-two week low of $45.00 and a fifty-two week high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). The business had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. Alnylam Pharmaceuticals’s quarterly revenue was up 116.6% on a year-over-year basis. During the same period last year, the firm posted ($1.32) EPS. equities research analysts anticipate that Alnylam Pharmaceuticals will post -6.81 earnings per share for the current fiscal year.
In related news, CEO John Maraganore sold 73,415 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total value of $9,610,023.50. Following the completion of the transaction, the chief executive officer now directly owns 223,125 shares in the company, valued at approximately $29,207,062.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Michael Mason sold 36,745 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the sale, the vice president now owns 6,352 shares of the company’s stock, valued at $835,859.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 146,409 shares of company stock worth $19,279,377. Insiders own 4.30% of the company’s stock.
A number of institutional investors have recently modified their holdings of ALNY. Prudential Financial Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 200 shares during the last quarter. Northern Trust Corp raised its position in Alnylam Pharmaceuticals by 5.0% in the 2nd quarter. Northern Trust Corp now owns 377,020 shares of the biopharmaceutical company’s stock worth $30,072,000 after purchasing an additional 17,862 shares during the period. Suntrust Banks Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $320,000. Parametric Portfolio Associates LLC increased its position in shares of Alnylam Pharmaceuticals by 8.2% during the second quarter. Parametric Portfolio Associates LLC now owns 64,943 shares of the biopharmaceutical company’s stock worth $5,180,000 after acquiring an additional 4,913 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Alnylam Pharmaceuticals by 59.1% during the second quarter. Dimensional Fund Advisors LP now owns 179,429 shares of the biopharmaceutical company’s stock worth $14,311,000 after acquiring an additional 66,651 shares during the period. 88.61% of the stock is owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.